Literature DB >> 30616404

Pro- and anti-tumorigenic functions of the senescence-associated secretory phenotype.

Lena Lau1, Gregory David1,2,3.   

Abstract

Introduction: Cellular senescence is a stable form of cell cycle exit. Though they no longer divide, senescent cells remain metabolically active and secrete a plethora of proteins collectively termed the senescence-associated secretory phenotype (SASP). Although senescence-associated cell cycle exit likely evolved as an anti-tumor mechanism, the SASP contains both anti- and pro-tumorigenic potential.Areas covered: In this review, we briefly discuss the discovery of senescent cells and its relationship to cancer and aging. We also describe the initiation and regulation of the SASP upon senescence stimulus onset. We focus on both the pro- and anti-tumorigenic properties of the SASP. Finally, we speculate on the potential benefits of therapy-induced senescence combined with selective SASP inhibition for the treatment of cancer.Expert opinion: Further identification and characterization of the SASP factors that are pro-tumorigenic and those that are anti-tumorigenic in specific contexts will be crucial in order to develop personalized therapeutics for the successful treatment of cancer.

Entities:  

Keywords:  Cancer; SASP; cellular senescence; inflammation; senescence-associated secretory phenotype; tumorigenesis

Year:  2019        PMID: 30616404      PMCID: PMC6614023          DOI: 10.1080/14728222.2019.1565658

Source DB:  PubMed          Journal:  Expert Opin Ther Targets        ISSN: 1472-8222            Impact factor:   6.902


  91 in total

1.  The DNA damage response induces inflammation and senescence by inhibiting autophagy of GATA4.

Authors:  Chanhee Kang; Qikai Xu; Timothy D Martin; Mamie Z Li; Marco Demaria; Liviu Aron; Tao Lu; Bruce A Yankner; Judith Campisi; Stephen J Elledge
Journal:  Science       Date:  2015-09-25       Impact factor: 47.728

2.  Oncogene-induced senescence is a DNA damage response triggered by DNA hyper-replication.

Authors:  Raffaella Di Micco; Marzia Fumagalli; Angelo Cicalese; Sara Piccinin; Patrizia Gasparini; Chiara Luise; Catherine Schurra; Massimiliano Garre'; Paolo Giovanni Nuciforo; Aaron Bensimon; Roberta Maestro; Pier Giuseppe Pelicci; Fabrizio d'Adda di Fagagna
Journal:  Nature       Date:  2006-11-30       Impact factor: 49.962

3.  DNA damage is able to induce senescence in tumor cells in vitro and in vivo.

Authors:  Robert H te Poele; Andrei L Okorokov; Lesley Jardine; Jeffrey Cummings; Simon P Joel
Journal:  Cancer Res       Date:  2002-03-15       Impact factor: 12.701

4.  cGAS is essential for cellular senescence.

Authors:  Hui Yang; Hanze Wang; Junyao Ren; Qi Chen; Zhijian J Chen
Journal:  Proc Natl Acad Sci U S A       Date:  2017-05-22       Impact factor: 11.205

5.  MTOR regulates the pro-tumorigenic senescence-associated secretory phenotype by promoting IL1A translation.

Authors:  Remi-Martin Laberge; Yu Sun; Arturo V Orjalo; Christopher K Patil; Adam Freund; Lili Zhou; Samuel C Curran; Albert R Davalos; Kathleen A Wilson-Edell; Su Liu; Chandani Limbad; Marco Demaria; Patrick Li; Gene B Hubbard; Yuji Ikeno; Martin Javors; Pierre-Yves Desprez; Christopher C Benz; Pankaj Kapahi; Peter S Nelson; Judith Campisi
Journal:  Nat Cell Biol       Date:  2015-07-06       Impact factor: 28.824

6.  DNA damage triggers a prolonged p53-dependent G1 arrest and long-term induction of Cip1 in normal human fibroblasts.

Authors:  A Di Leonardo; S P Linke; K Clarkin; G M Wahl
Journal:  Genes Dev       Date:  1994-11-01       Impact factor: 11.361

7.  Telomere shortening triggers senescence of human cells through a pathway involving ATM, p53, and p21(CIP1), but not p16(INK4a).

Authors:  Utz Herbig; Wendy A Jobling; Benjamin P C Chen; David J Chen; John M Sedivy
Journal:  Mol Cell       Date:  2004-05-21       Impact factor: 17.970

Review 8.  The senescence-associated secretory phenotype: the dark side of tumor suppression.

Authors:  Jean-Philippe Coppé; Pierre-Yves Desprez; Ana Krtolica; Judith Campisi
Journal:  Annu Rev Pathol       Date:  2010       Impact factor: 23.472

9.  HMGB2 orchestrates the chromatin landscape of senescence-associated secretory phenotype gene loci.

Authors:  Katherine M Aird; Osamu Iwasaki; Andrew V Kossenkov; Hideki Tanizawa; Nail Fatkhutdinov; Benjamin G Bitler; Linh Le; Gretchen Alicea; Ting-Lin Yang; F Brad Johnson; Ken-Ichi Noma; Rugang Zhang
Journal:  J Cell Biol       Date:  2016-10-31       Impact factor: 10.539

10.  Palbociclib (PD-0332991), a selective CDK4/6 inhibitor, restricts tumour growth in preclinical models of hepatocellular carcinoma.

Authors:  Julien Bollard; Verónica Miguela; Marina Ruiz de Galarreta; Anu Venkatesh; C Billie Bian; Mark P Roberto; Victoria Tovar; Daniela Sia; Pedro Molina-Sánchez; Christie B Nguyen; Shigeki Nakagawa; Josep M Llovet; Yujin Hoshida; Amaia Lujambio
Journal:  Gut       Date:  2016-11-14       Impact factor: 23.059

View more
  17 in total

Review 1.  Growth hormone in the tumor microenvironment.

Authors:  Vera Chesnokova; Shlomo Melmed
Journal:  Arch Endocrinol Metab       Date:  2019 Nov-Dec       Impact factor: 2.309

2.  ALDH2 deficiency promotes alcohol-associated liver cancer by activating oncogenic pathways via oxidized DNA-enriched extracellular vesicles.

Authors:  Wonhyo Seo; Yanhang Gao; Yong He; Jing Sun; Hongqin Xu; Dechun Feng; Seol Hee Park; Young-Eun Cho; Adrien Guillot; Tianyi Ren; Ruihong Wu; Jingyun Wang; Seung-Jin Kim; Seonghwan Hwang; Suthat Liangpunsakul; Yingzi Yang; Junqi Niu; Bin Gao
Journal:  J Hepatol       Date:  2019-07-04       Impact factor: 25.083

Review 3.  The origins of cancer cell dormancy.

Authors:  Jorge Morales-Valencia; Gregory David
Journal:  Curr Opin Genet Dev       Date:  2022-04-29       Impact factor: 4.665

4.  Liver osteopontin is required to prevent the progression of age-related nonalcoholic fatty liver disease.

Authors:  Beatriz Gómez-Santos; Diego Saenz de Urturi; Maitane Nuñez-García; Francisco Gonzalez-Romero; Xabier Buque; Igor Aurrekoetxea; Virginia Gutiérrez de Juan; Maria J Gonzalez-Rellan; Carmelo García-Monzón; Águeda González-Rodríguez; Lorena Mosteiro; Gaizka Errazti; Patricia Mifsut; Sonia Gaztambide; Luis Castaño; Cesar Martin; Rubén Nogueiras; María L Martinez-Chantar; Wing-Kin Syn; Patricia Aspichueta
Journal:  Aging Cell       Date:  2020-07-07       Impact factor: 9.304

Review 5.  The immunomodulatory effects of endocrine therapy in breast cancer.

Authors:  Huanhuan Huang; Jun Zhou; Hailong Chen; Jiaxin Li; Chao Zhang; Xia Jiang; Chao Ni
Journal:  J Exp Clin Cancer Res       Date:  2021-01-07

6.  Targeting sphingosine kinase 1 (SK1) enhances oncogene-induced senescence through ceramide synthase 2 (CerS2)-mediated generation of very-long-chain ceramides.

Authors:  Magali Trayssac; Christopher J Clarke; Jeffrey L Stith; Justin M Snider; Naomi Newen; Christopher R Gault; Yusuf A Hannun; Lina M Obeid
Journal:  Cell Death Dis       Date:  2021-01-04       Impact factor: 8.469

Review 7.  Senescent tumor cells: an overlooked adversary in the battle against cancer.

Authors:  Soon Sang Park; Yong Won Choi; Jang-Hee Kim; Hong Seok Kim; Tae Jun Park
Journal:  Exp Mol Med       Date:  2021-12-16       Impact factor: 8.718

Review 8.  Pancreatic Cancer and Cellular Senescence: Tumor Microenvironment under the Spotlight.

Authors:  Michela Cortesi; Michele Zanoni; Francesca Pirini; Maria Maddalena Tumedei; Sara Ravaioli; Ilario Giovanni Rapposelli; Giovanni Luca Frassineti; Sara Bravaccini
Journal:  Int J Mol Sci       Date:  2021-12-27       Impact factor: 5.923

Review 9.  NGAL as a Potential Target in Tumor Microenvironment.

Authors:  Elvira Crescenzi; Antonio Leonardi; Francesco Pacifico
Journal:  Int J Mol Sci       Date:  2021-11-15       Impact factor: 5.923

10.  Radiation-Induced Senescence Reprograms Secretory and Metabolic Pathways in Colon Cancer HCT-116 Cells.

Authors:  Chandrasekharam N Nagineni; Sarwat Naz; Rajani Choudhuri; Gadisetti V R Chandramouli; Murali C Krishna; Jeffrey R Brender; John A Cook; James B Mitchell
Journal:  Int J Mol Sci       Date:  2021-05-03       Impact factor: 5.923

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.